Home
| Log in or Sign Up for full access
| Tracked Organizations
| Recent Tracked Activities
Recent Activities
Activities between Nov. 15, 2024, 7:47 p.m. and Nov. 22, 2024, 7:47 p.m.
from: Label And Packaging.
Click on a document link to see the original source document.
Click on the name of an organization to see more organization linkages and timelines.
Document Date: Nov. 22, 2024, 4:30 a.m. / Source: GlobeNewswire
Activity Class: PartnershipActivity
/ Region: Japan
Partnership:
- Takeda
/ Industry: Biopharmaceutical And Biotech Industry, Biotech And Technology and 13 more
- HUTCHMED
/ Industry: Biopharmaceutical And Biotech Industry, Biotech And Technology and 2 more
- HUTCHMED
/ Industry: Biopharmaceutical And Biotech Industry, Biotech And Technology and 2 more
- Takeda
/ Industry: Biopharmaceutical And Biotech Industry, Biotech And Technology and 13 more
Document Extract: On the launch of FRUZAQLA® in Japan by Takeda, Dr Weiguo Su, Chief Executive Officer and Chief Scientific Officer of HUTCHMED, said: "The launch of FRUZAQLA® in Japan highlights the continued progress of our partnership with Takeda across the globe. Takeda is well positioned to build on more than a decade of leadership in the treatment of metastatic CRC in Japan and bring a differentiated treatment option in FRUZAQLA® to patients ." The launch of FRUZAQLA® in Japan follows its approval in September 2024, primarily based on results from the Phase III FRESCO-2 trial conducted in the US, Europe, Japan and Australia. Data from FRESCO-2 were published in The Lancet in June 2023. Takeda has the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside of mainland China, Hong Kong and Macau, and markets under the FRUZAQLA® brand name.
Document Source: https://www.globenewswire.com/news-release/2024/11/22/2985718/0/en/HUTCHMED-Announces-Launch-by-Takeda-of-FRUZAQLA-fruquintinib-in-Japan.html
(archive.org page /
archive.org listing)
Document Date: Nov. 19, 2024, 2:06 p.m. / Source: GlobeNewswire
Activity Class: CorporateFinanceActivity
/ Type: Merger
/ Region: Utah
Buyer:
Participant:
- R1 RCM
/ Industry: Caretech, Healthcare Services And Healthcare Information Technology and 3 more
Target:
- R1 RCM
/ Industry: Caretech, Healthcare Services And Healthcare Information Technology and 3 more
Document Extract: MURRAY, Utah, Nov. 19, 2024 (GLOBE NEWSWIRE) - R1 RCM Inc. ("R1") , a leader in automating revenue management for healthcare providers, today announced that investment funds affiliated with TowerBrook Capital Partners ("TowerBrook") and Clayton, Dubilier & Rice ("CD & R") have completed their previously announced acquisition of R1.
Document Source: https://www.globenewswire.com/news-release/2024/11/19/2983728/0/en/TowerBrook-and-CD-R-Complete-Acquisition-of-R1-RCM.html
(archive.org page /
archive.org listing)
Document Date: Nov. 19, 2024, 2:06 p.m. / Source: GlobeNewswire
Activity Class: CorporateFinanceActivity
/ Type: Merger
/ Region: Utah
Buyer:
Participant:
- R1 RCM
/ Industry: Caretech, Healthcare Services And Healthcare Information Technology and 3 more
Document Extract: MURRAY, Utah, Nov. 19, 2024 (GLOBE NEWSWIRE) - R1 RCM Inc. ("R1") , a leader in automating revenue management for healthcare providers, today announced that investment funds affiliated with TowerBrook Capital Partners ("TowerBrook") and Clayton, Dubilier & Rice ("CD & R") have completed their previously announced acquisition of R1.
Document Source: https://www.globenewswire.com/news-release/2024/11/19/2983728/0/en/TowerBrook-and-CD-R-Complete-Acquisition-of-R1-RCM.html
(archive.org page /
archive.org listing)
Archive.org page links will work if the page has already been archived by archive.org, but we can't guarantee which pages archive.org has archived so far.
Treat sameAsNameOnly relationship as same? Yes
(Turn Off)
Site Stats
| About (includes privacy and cookie notices)
(c) by 1145, 2023-2024. Data licensed under the Open Database License.
Please send an email if you need a non-share-alike license and/or you need API access.